Abstract CT269: A highly sensitive and specific PARylation assay confirms significant and durable target engagement by AZD5305 in patients
Sign Up to like & getrecommendations! Published in 2023 at "Cancer Research"
DOI: 10.1158/1538-7445.am2023-ct269
Abstract: Background AZD5305 is a selective PARP1 inhibitor (PARPi) generated for improved therapeutic index compared with non-selective PARPi. Measurement of PARylation inhibition has been used to determine the pharmacodynamics (PD) of PARPi in clinical trials, but… read more here.
Keywords: inhibition; parylation inhibition; parylation; highly sensitive ... See more keywords